Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8681338 | 0.88 | PPARG (0.38) | PPARGRXRACYP1A2GLACYP3A4 | |
| SCHEMBL5712317 | 0.87 | PPARG (0.48) | PPARGPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5712320 | 0.87 | PPARG (0.48) | PPARGPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7937486 | 0.86 | MEN1 (0.33) | PPARGRXRACYP1A2GLACYP3A4 | |
| SCHEMBL7632675 | 0.86 | PPARG (0.39) | PPARGRXRAMAPT | |
| SCHEMBL9710902 | 0.85 | PPARG (0.42) | PPARGPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7930958 | 0.84 | PPARG (0.35) | PPARGPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7939964 | 0.83 | PPARG (0.32) | PPARGRXRACYP1A2GLACYP3A4 | |
| SCHEMBL7942618 | 0.82 | PPARG (0.47) | LRRK2PPARGPSEN1PSEN2APH1B | |
| SCHEMBL7639124 | 0.79 | RET (0.34) | PPARGRXRAAMY1AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-09-06 | — | — | US | disclosed |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-07-05 | — | — | US | disclosed |
| US-5958982-A | Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5902827-A | Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS (US) | 1999-05-11 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, FFAR3 | LRRK2 3358/4885PPARG 31/4885PSEN1 2502/4885 |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | LRRK2 4849/4885PPARG 18/4885PSEN1 2625/4885 |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, IAPP | LRRK2 4511/4885PPARG 32/4885PSEN1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.